| Literature DB >> 35310767 |
Kyoichi Adachi1, Norihisa Ishimura2, Takumi Notsu1, Kanako Kishi1, Tomoko Mishiro1, Kazunari Sota1, Nahoko Nagano3, Shunji Ishihara2.
Abstract
Objective: Lymphoid hyperplasia is endoscopically observed as multiple small whitish round nodules or spots. This retrospective study was performed to examine the prevalence of that finding in patients with Barrett's epithelium and its relationship with the status of H. pylori infection.Entities:
Keywords: Barrett's esophagus; Helicobacter pylori; blue laser imaging; endoscopy; lymphoid hyperplasia
Year: 2021 PMID: 35310767 PMCID: PMC8828233 DOI: 10.1002/deo2.15
Source DB: PubMed Journal: DEN open ISSN: 2692-4609
FIGURE 1Endoscopic findings of cardiac portion in subjects positive for H. pylori infection ((a) white light image, (b) blue laser imaging [BLI], (c) linked color imaging [LCI], (d) BLI image 2 years after eradication for H. pylori]. Multiple small whitish round nodules, an endoscopic finding indicating lymphoid hyperplasia, were easily recognized with BLI. In addition, the distal ends of palisade vessels were observed in the area of lymphoid hyperplasia as well as on the oral side of gastric folds with endoscopy using LCI, suggesting that endoscopic findings showing lymphoid hyperplasia can be confirmed in an area of Barrett's epithelium. Endoscopic findings of lymphoid hyperplasia has been diminished after successful eradication for H. pylori
FIGURE 2Histology results of biopsied samples obtained from cardiac portion in patients with multiple small whitish round nodules shown by endoscopy. Lymphocyte aggregation was observed deep in the area of mucosa
FIGURE 3Flow of subject selection for this study
Characteristics of subjects with endoscopic findings of lymphoid hyperplasia in Barrett's epithelium
| Lymphoid hyperplasia | |||
|---|---|---|---|
| Positive ( | Negative ( |
| |
| Gender, male/female | 251/151 | 1058/424 | <0.001 |
| Age, years | 53.7 ± 9.0 | 56.0 ± 9.2 | <0.001 |
|
| <0.001 | ||
| Negative | 0 | 657 (44.3%) | |
| Positive | 78 (19.4%) | 83 (5.6%) | |
| Post‐eradication | 324 (80.6%) | 742 (50.1%) | |
| Gastric mucosal atrophy | <0.001 | ||
| Mild | 184 (45.8%) | 1091 (73.6%) | |
| Moderate | 181 (45.0%) | 305 (20.6%) | |
| Severe | 37 (9.2%) | 86 (5.8%) | |
| Nodular gastritis | 8 (2.0%) | 6 (0.4%) | 0.001 |
| Reflux esophagitis | 40 (10.0%) | 310 (20.9%) | 0.005 |
| Anti‐secretory therapy | 15 (3.7%) | 114 (7.7%) | <0.001 |
| PPI/H2RA usage | 11/4 | 104/10 | |
Data are expressed as the mean ± SD or number of subjects. Gastric mucosal atrophy was evaluated using the classification of Kimura and Takemoto (C1‐C2: mild, C3‐O1: moderate, O2‐O3: severe). Reflux esophagitis: Grade A‐D of the Los Angeles classification.
Abbreviations: H2RA, H2 receptor antagonist; PPI, proton pump inhibitor.
FIGURE 4H. pylori‐positive and post‐eradicated subjects with endoscopic findings of lymphoid hyperplasia in Barrett's epithelium. The timing of H. pylori eradication could not be clarified in six subjects, and those were excluded from the analysis of duration after H. pylori eradication
Multiple logistic regression analysis of subjects with endoscopic findings of lymphoid hyperplasia in Barrett's epithelium classified as positive for H. pylori infection or post‐eradicated status
| Odds ratio | 95% CI |
| |
|---|---|---|---|
| Gender (female) | 1.585 | 1.217–2.063 | <0.001 |
| Age | 0.946 | 0.932–0.960 | <0.001 |
| Gastric mucosal atrophy (vs. mild atrophy) | |||
| Moderate | 1.600 | 1.224–2.090 | <0.001 |
| Severe | 1.648 | 1.045–2.599 | 0.032 |
|
| |||
| Post‐eradication | 0.612 | 0.429–0.872 | 0.007 |
Subjects without H. pylori infection were excluded from analysis, as no endoscopic findings of lymphoid hyperplasia were observed in those. Gastric mucosal atrophy was evaluated using the classification of Kimura and Takemoto (C1‐C2: mild, C3‐O1: moderate, O2‐O3: severe).
Multiple logistic regression analysis of subjects with endoscopic findings of lymphoid hyperplasia in Barrett's epithelium classified as post‐eradicated status following H. pylori infection
| Odds ratio | 95% CI |
| |
|---|---|---|---|
| Gender (female) | 1.571 | 1.177–2.098 | 0.002 |
| Age | 0.955 | 0.939–0.971 | <0.001 |
| Gastric mucosal atrophy (vs. mild atrophy) | |||
| Moderate | 1.309 | 0.975–1.758 | 0.073 |
| Severe | 1.443 | 0.877–2.375 | 0.149 |
| Duration after eradication (years) | 0.933 | 0.904–0.963 | <0.001 |
Six subjects for whom the timing of H. pylori eradication could not be clarified were excluded from analysis. Gastric mucosal atrophy was evaluated using the classification of Kimura and Takemoto (C1‐C2: mild, C3‐O1: moderate, O2‐O3: severe).